Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon

Scandinavian Journal of Gastroenterology

Volumn 41, Issue 9, 2006, Pages 1087-1094

  Veldt, Bart J ^a   Hansen, Bettina E ^a   Ikeda, Kenji ^b   Verhey, Elke ^a   Suzuki, Hiroshi ^c   Schalm, Solko W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b TORANOMON HOSPITAL   (Japan)

^c UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Chronic hepatitis C; G estimation; hepatocellular carcinoma; interferon; non responder; SNMC

Indexed keywords

ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; GLYCYRRHIZIC ACID; INTERFERON;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; JAPAN; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK FACTOR; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; GLYCYRRHIZIC ACID; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; INJECTIONS, INTRAVENOUS; INTERFERONS; JAPAN; LIVER NEOPLASMS; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 34248996254     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520600641365     Document Type: Article

References (21)

1. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825–32
2. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–65
3. Hadziyannis SJ, Sette H, Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346–55
4. Veldt BJ, Saracco G, Boyer N, Camma C, Bellobuono A, Hopf U, et al. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut 2004; 53: 1504–8
5. Shiffman ML, Hofmann CM, Contos MJ, Luketic VA, Sanyal AJ, Sterling RK, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999; 117: 1164–72
6. Hoofnagle JH, Ghany MG, Kleiner DE, Doo E, Heller T, Promrat K, et al. Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology 2003; 38: 66–74
7. Yoshikawa M, Toyohara M, Ueda S, Shiroi A, Takeuchi H, Nishiyama T, et al. Glycyrrhizin inhibits TNF-induced, but not Fas-mediated, apoptosis in the human hepatoblastoma line HepG2. Biol Pharm Bull 1999; 22: 951–5
8. Okamoto T. The protective effect of glycyrrhizin on anti-Fas antibody-induced hepatitis in mice. Eur J Pharmacol 2000; 387: 229–32
9. Lewis JH. Licorice for hepatitis C: yum-yum or just ho-hum?. Am J Gastroenterol 2001; 96: 2291–2
10. van Rossum TG, de Jong FH, Hop WC, Boomsma F, Schalm SW. Pseudo-aldosteronism” induced by intravenous glycyrrhizin treatment of chronic hepatitis C patients. J Gastroenterol Hepatol 2001; 16: 789–95
11. van Rossum TG, Vulto AG, Hop WC, Schalm SW. Glycyrrhizin-induced reduction of ALT in European patients with chronic hepatitis C. Am J Gastroenterol 2001; 96: 2432–7
12. Fattovich G, Giustina G, Degos F, Diodati G, Tremolada F, Nevens F, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1997; 27: 201–5
13. Hernan MA, Hernandez-Diaz S, Robins JM. A structural approach to selection bias. Epidemiology 2004; 15: 615–25
14. Yoshida H, Tateishi R, Arakawa Y, Sata M, Fujiyama S, Nishiguchi S, et al. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut 2004; 53: 425–30
15. Okanoue T, Itoh Y, Kirishima T, Daimon Y, Toyama T, Morita A, et al. Transient biochemical response in interferon therapy decreases the development of hepatocellular carcinoma for five years and improves the long-term survival of chronic hepatitis C patients. Hepatol Res 2002; 23: 62–77
16. Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29: 1124–30
17. Moriyama M, Matsumura H, Aoki H, Shimizu T, Yamagami H, Shioda A, et al. Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy. Liver Int 2005; 25: 85–90
18. Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med 2003; 348: 645–50
19. Witteman JC, D'Agostino RB, Stijnen T, Kannel WB, Cobb JC, de Ridder MA, et al. G-estimation of causal effects: isolated systolic hypertension and cardiovascular death in the Framingham Heart Study. Am J Epidemiol 1998; 148: 390–401
20. Robins JM, Blevins D, Ritter G, Wulfsohn M. G-estimation of the effect of prophylaxis therapy for Pneumocystis carinii pneumonia on the survival of AIDS patients. Epidemiology 1992; 3: 319–36
21. Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, Koida I, et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997; 79: 1494–500